Biotransformation and bioactivation reactions–2018 literature highlights

S. Cyrus Khojasteh, Namandje N Bumpus, James P. Driscoll, Grover P. Miller, Kaushik Mitra, Ivonne M.C.M. Rietjens, Donglu Zhang

Research output: Contribution to journalReview article

Abstract

In the past three decades, ADME sciences have become an integral component of the drug discovery and development process. At the same time, the field has continued to evolve, thus, requiring ADME scientists to be knowledgeable of and engage with diverse aspects of drug assessment: from pharmacology to toxicology, and from in silico modeling to in vitro models and finally in vivo models. Progress in this field requires deliberate exposure to different aspects of ADME; however, this task can seem daunting in the current age of mass information. We hope this review provides a focused and brief summary of a wide array of critical advances over the past year and explains the relevance of this research (Table 1). We divided the articles into categories of (1) drug optimization, (2) metabolites and drug metabolizing enzymes, and (3) bioactivation. This annual review is the fourth of its kind (Baillie et al. 2016; Khojasteh et al. 2017, 2018). We have followed the same format we used in previous years in terms of the selection of articles and the authoring of each section. This effort in itself also continues to evolve. I am pleased that Rietjens, Miller, and Mitra have again contributed to this annual review. We would like to welcome Namandjé N. Bumpus, James P. Driscoll, and Donglu Zhang as authors for this year’s issue. We strive to maintain a balance of authors from academic and industry settings. We would be pleased to hear your opinions of our commentary, and we extend an invitation to anyone who would like to contribute to a future edition of this review. Cyrus Khojasteh, on behalf of the authors.

Original languageEnglish (US)
JournalDrug Metabolism Reviews
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Biotransformation
Pharmaceutical Preparations
Drug Discovery
Computer Simulation
Toxicology
Industry
Pharmacology
Enzymes
Research

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Khojasteh, S. C., Bumpus, N. N., Driscoll, J. P., Miller, G. P., Mitra, K., Rietjens, I. M. C. M., & Zhang, D. (Accepted/In press). Biotransformation and bioactivation reactions–2018 literature highlights. Drug Metabolism Reviews. https://doi.org/10.1080/03602532.2019.1615937

Biotransformation and bioactivation reactions–2018 literature highlights. / Khojasteh, S. Cyrus; Bumpus, Namandje N; Driscoll, James P.; Miller, Grover P.; Mitra, Kaushik; Rietjens, Ivonne M.C.M.; Zhang, Donglu.

In: Drug Metabolism Reviews, 01.01.2019.

Research output: Contribution to journalReview article

Khojasteh, S. Cyrus ; Bumpus, Namandje N ; Driscoll, James P. ; Miller, Grover P. ; Mitra, Kaushik ; Rietjens, Ivonne M.C.M. ; Zhang, Donglu. / Biotransformation and bioactivation reactions–2018 literature highlights. In: Drug Metabolism Reviews. 2019.
@article{52f27772b32d46f58c4251daadc41761,
title = "Biotransformation and bioactivation reactions–2018 literature highlights",
abstract = "In the past three decades, ADME sciences have become an integral component of the drug discovery and development process. At the same time, the field has continued to evolve, thus, requiring ADME scientists to be knowledgeable of and engage with diverse aspects of drug assessment: from pharmacology to toxicology, and from in silico modeling to in vitro models and finally in vivo models. Progress in this field requires deliberate exposure to different aspects of ADME; however, this task can seem daunting in the current age of mass information. We hope this review provides a focused and brief summary of a wide array of critical advances over the past year and explains the relevance of this research (Table 1). We divided the articles into categories of (1) drug optimization, (2) metabolites and drug metabolizing enzymes, and (3) bioactivation. This annual review is the fourth of its kind (Baillie et al. 2016; Khojasteh et al. 2017, 2018). We have followed the same format we used in previous years in terms of the selection of articles and the authoring of each section. This effort in itself also continues to evolve. I am pleased that Rietjens, Miller, and Mitra have again contributed to this annual review. We would like to welcome Namandj{\'e} N. Bumpus, James P. Driscoll, and Donglu Zhang as authors for this year’s issue. We strive to maintain a balance of authors from academic and industry settings. We would be pleased to hear your opinions of our commentary, and we extend an invitation to anyone who would like to contribute to a future edition of this review. Cyrus Khojasteh, on behalf of the authors.",
author = "Khojasteh, {S. Cyrus} and Bumpus, {Namandje N} and Driscoll, {James P.} and Miller, {Grover P.} and Kaushik Mitra and Rietjens, {Ivonne M.C.M.} and Donglu Zhang",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/03602532.2019.1615937",
language = "English (US)",
journal = "Drug Metabolism Reviews",
issn = "0360-2532",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Biotransformation and bioactivation reactions–2018 literature highlights

AU - Khojasteh, S. Cyrus

AU - Bumpus, Namandje N

AU - Driscoll, James P.

AU - Miller, Grover P.

AU - Mitra, Kaushik

AU - Rietjens, Ivonne M.C.M.

AU - Zhang, Donglu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the past three decades, ADME sciences have become an integral component of the drug discovery and development process. At the same time, the field has continued to evolve, thus, requiring ADME scientists to be knowledgeable of and engage with diverse aspects of drug assessment: from pharmacology to toxicology, and from in silico modeling to in vitro models and finally in vivo models. Progress in this field requires deliberate exposure to different aspects of ADME; however, this task can seem daunting in the current age of mass information. We hope this review provides a focused and brief summary of a wide array of critical advances over the past year and explains the relevance of this research (Table 1). We divided the articles into categories of (1) drug optimization, (2) metabolites and drug metabolizing enzymes, and (3) bioactivation. This annual review is the fourth of its kind (Baillie et al. 2016; Khojasteh et al. 2017, 2018). We have followed the same format we used in previous years in terms of the selection of articles and the authoring of each section. This effort in itself also continues to evolve. I am pleased that Rietjens, Miller, and Mitra have again contributed to this annual review. We would like to welcome Namandjé N. Bumpus, James P. Driscoll, and Donglu Zhang as authors for this year’s issue. We strive to maintain a balance of authors from academic and industry settings. We would be pleased to hear your opinions of our commentary, and we extend an invitation to anyone who would like to contribute to a future edition of this review. Cyrus Khojasteh, on behalf of the authors.

AB - In the past three decades, ADME sciences have become an integral component of the drug discovery and development process. At the same time, the field has continued to evolve, thus, requiring ADME scientists to be knowledgeable of and engage with diverse aspects of drug assessment: from pharmacology to toxicology, and from in silico modeling to in vitro models and finally in vivo models. Progress in this field requires deliberate exposure to different aspects of ADME; however, this task can seem daunting in the current age of mass information. We hope this review provides a focused and brief summary of a wide array of critical advances over the past year and explains the relevance of this research (Table 1). We divided the articles into categories of (1) drug optimization, (2) metabolites and drug metabolizing enzymes, and (3) bioactivation. This annual review is the fourth of its kind (Baillie et al. 2016; Khojasteh et al. 2017, 2018). We have followed the same format we used in previous years in terms of the selection of articles and the authoring of each section. This effort in itself also continues to evolve. I am pleased that Rietjens, Miller, and Mitra have again contributed to this annual review. We would like to welcome Namandjé N. Bumpus, James P. Driscoll, and Donglu Zhang as authors for this year’s issue. We strive to maintain a balance of authors from academic and industry settings. We would be pleased to hear your opinions of our commentary, and we extend an invitation to anyone who would like to contribute to a future edition of this review. Cyrus Khojasteh, on behalf of the authors.

UR - http://www.scopus.com/inward/record.url?scp=85070803521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070803521&partnerID=8YFLogxK

U2 - 10.1080/03602532.2019.1615937

DO - 10.1080/03602532.2019.1615937

M3 - Review article

C2 - 31170851

AN - SCOPUS:85070803521

JO - Drug Metabolism Reviews

JF - Drug Metabolism Reviews

SN - 0360-2532

ER -